INC Research Implements DrugDev’s SiteCloud Platform

INC Research has entered a strategic collaboration with DrugDev aimed at driving increased efficiencies in clinical trials through greater access to and management of critical investigator and site data. INC Research has completed integration and implementation of DrugDev’s SiteCloud platform, the same technology used by TransCelerate’s Investigator Registry (launching later this year) and the Investigator Databank, to facilitate more efficient feasibility, site selection and study start-up processes.

Using a universal identifier known as the DrugDev Golden Number, the SiteCloud platform matches and masters data from numerous disparate sources (such as INC’s internal experience, the DrugDev Network of 80,000 opted-in global investigators across 115 countries and trusted third-party resources) to create a virtual private database (VPD) with precise site and investigator profiles that will be used to make evidence-based decisions. SiteCloud enables INC to make evidence-driven site selection decisions, while the DrugDev Golden Number enables INC to collaborate and integrate more efficiently with pharma customers.

“INC Research is continuously looking to advance clinical research and patient and site engagement through innovation,” said Clare Grace, vice president, Site and Patient Access. “DrugDev provides cutting-edge solutions that help drive the biopharmaceutical industry forward. Cloud-based offerings like SiteCloud are the latest examples of the tools and resources INC uses to share critical investigative site data with our customers and drive increased efficiencies at critical points along the drug development continuum.”

“Real change will only come to the clinical research industry through meaningful collaboration and the widespread adoption of technology standards such as the DrugDev Golden Number, so naturally we could not be more excited to work with INC Research on this essential initiative,” said Ibraheem Mahmood, president and chief executive officer of DrugDev. “As a platform-agnostic leader, INC is committed to leveraging future-proof technologies that best meet customer requirements, and we are honored that they have chosen SiteCloud as their preferred platform for site and investigator data sharing and management.”